Continuous Bioprocessing for Bispecifics: Driving Innovation in Therapeutic Antibody Production

Bispecific and multispecific antibodies represent a transformative class of therapeutics, offering dual-targeting capabilities for enhanced efficacy in oncology and other indications. However, their structural complexity introduces significant challenges in design, manufacturability, and cost-effective production. This white paper outlines Just – Evotec Biologics’ integrated approach to overcoming these hurdles through advanced technologies and continuous bioprocessing.